Back | Next |
home / stock / jagx / jagx message board
Subject | By | Source | When |
---|---|---|---|
Would you 'consume' your biggest ever catalyst to | ShadowDiviner72 | investorshub | 06/05/2024 10:45:33 AM |
I could have said the same about the | DanDosh | investorshub | 06/05/2024 10:42:24 AM |
Why are you being so stupid? Why would | ShadowDiviner72 | investorshub | 06/05/2024 10:31:59 AM |
Few? It's 13% of the outstanding shares that | DanDosh | investorshub | 06/05/2024 10:25:48 AM |
I agree with everything in your post. Moreover, | PhantomOasis61 | investorshub | 06/05/2024 10:00:23 AM |
Are you new to the stock market? We | ShadowDiviner72 | investorshub | 06/05/2024 8:30:38 AM |
Yeah, well, i'm afraid they will tie somehow | DanDosh | investorshub | 06/05/2024 8:18:38 AM |
I do agree with you. There was a | ShadowDiviner72 | investorshub | 06/05/2024 7:57:15 AM |
There was apparently a statistical problem in conjunction | PhantomOasis61 | investorshub | 06/04/2024 11:25:27 PM |
If the trial is done, what is the | oilin07 | investorshub | 06/04/2024 10:48:30 PM |
Man I hope so getting tired on the | scho1560 | investorshub | 06/04/2024 9:23:57 PM |
Since the list of late breaking abstracts sans | PhantomOasis61 | investorshub | 06/04/2024 8:08:35 PM |
A positive observed in the chart: while | timberwolf7 | investorshub | 06/04/2024 7:23:03 PM |
Broke a rule of mine (which I do | timberwolf7 | investorshub | 06/04/2024 3:11:36 PM |
Will $4.05 - $4.20 range continue to hold?? | timberwolf7 | investorshub | 06/04/2024 10:08:26 AM |
Yeah 3 weeks ago.. mid may.. study completion | ShadowDiviner72 | investorshub | 06/03/2024 6:30:04 PM |
Ah thanks for pointing that out, was glancing | SonicTheHedgeFun | investorshub | 06/03/2024 5:56:48 PM |
That has the date of May 22, 2024. | DanDosh | investorshub | 06/03/2024 5:44:58 PM |
I know all of that, my main gripe | DanDosh | investorshub | 06/03/2024 5:39:10 PM |
Um, the Frankfurt Exchange says its trading at | SonicTheHedgeFun | investorshub | 06/03/2024 5:33:42 PM |
News, Short Squeeze, Breakout and More Instantly...
Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here ...
New patents issued for core rare disease target indications for crofelemer Napo has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (...
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific ...